Tubulointerstitial damage and progression of renal failure

Kidney International

Volumn 68, Issue SUPPL. 99, 2005, Pages

  Rodríguez Iturbe, Bernardo ^a   Johnson, Richard J ^a   Herrera Acosta, Jaime ^a  

^a NONE

Author keywords

Renal function; Tubulointerstitial damage; Tubulointerstitial fibrosis

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B ALPHA; IMATINIB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTRALIZING ANTIBODY; NITRIC OXIDE; OSTEOGENIC PROTEIN 1; PIRFENIDONE; RAPAMYCIN; RELAXIN; RETINOID; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VITAMIN D; IMMUNOSUPPRESSIVE AGENT;

CONFERENCE PAPER; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; ENZYME INHIBITION; FIBROSING ALVEOLITIS; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TUBULE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; ANGIOGENESIS; ANIMAL; CHRONIC KIDNEY FAILURE; KIDNEY; PATHOPHYSIOLOGY; REVIEW; VASCULARIZATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DISEASE PROGRESSION; ERYTHROPOIETIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE; KIDNEY FAILURE, CHRONIC; NEOVASCULARIZATION, PHYSIOLOGIC; NEPHRITIS, INTERSTITIAL;

EID: 33748291391     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09915.x     Document Type: Conference Paper

References (59)

1. RISDON RA, SLOPER JC, DE WARDENER HE: Relationship between renal function and histological changes found in renal biopsy specimens from patients with persistent glomerular nephritis. Lancet 2:363-366, 1968
2. SCHAINUCK LI, STRICKER GE, CUTLER RE, BENDITT EP: Structural-functional correlations in renal disease. II. The correlations. Human Pathol 1:631-641, 1970
3. MACKENSEN-HAEN S, BADER R, GRUND KE, BOHLE A: Correlations between renal cortical interstitial fibrosis, atrophy of the proximal tubules and impairment of the glomerular filtration rate. Clin Nephrol 15:167-171, 1981
4. NATH KA: Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20:1-17, 1992
5. GILBERT RE, COOPER ME: The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int 56:1627-1637, 1999
6. GANDHI M, OLSON JL, MEYER TW: Contribution of tubular injury to loss of remnant kidney function. Kidney Int 54:1157-1165, 1998
7. KRIZ W, HOSSER H, HÄHNEL B, et al: From segmental glomerulosclerosis to total nephron degeneration and interstitial fibrosis: A histopathological study in rat models and human glomerulopathies. Nephrol Dial Transpl 13:2781-2798, 1998
8. KRIZ W, LEHIR M: Pathways to nephron loss starting from glomerular diseases-Insights from animal models. Kidney Int 67:404-419, 2005
9. ZANDI-NEJAD K, EDDY AA, GLASSOCK RJ, BRENNER BM: Why is proteinuria an ominous biomarker of progressive kidney disease? Kidney Int Suppl 92:S76-S89, 2004
10. MORITA Y, NOMURA A, YUZAWA Y, et al: The role of complement in the pathogenesis of tubulointerstitial lesions in rat mesangial proliferative glomerulonephritis. J Am Soc Nephrol 8:1363-1372, 1997
11. NANGAKU M, PIPPIN J, COUSER WG: Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephritic syndrome. J Am Soc Nephrol 10:2323-2331, 1999
12. NORMAN JT, CLARK IM, GARCIA PL: Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 58:2351-2366, 2000
13. MANOTHAM K, TANAKA T, MATSUMOTO M, et al: Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 65:871-880, 2004
14. KAHN S, CLEVELAND RP, KOCH CJ, SCHELLING JR: Hypoxia induces renal tubular cell apoptosis in chronic renal disease. Lab Invest 79:1089-1099, 1999
15. EDDY AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7:2495-2508, 1996
16. RODRÍGUEZ-ITURBE B, PONS H, HERRERA-ACOSTA J, JOHNSON RJ: The role of immunocompetent cells in non-immune renal diseases. Kidney Int 59:1626-1640, 2001
17. IWANO M, NEILSON EG: Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 13:279-284, 2004
18. LIU Y: Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanisms and therapeutic intervention. J Amer Soc Nephrol 25:1-12, 2004
19. STRUTZ F, OKADA H, LO CW, et al: Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 130:393-405, 1995
20. NG YY, HUANG TP, YANG WC, et al: Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 54:864-876, 1998
21. YANG J, SHUKTZ RW, MARS WM, et al: Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 110:1525-1538, 2002
22. RODRIGUEZ-ITURBE B, SATO T, QUIROZ Y, VAZIRI ND: AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia and glomerulosclerosis in the Imai rat. Kidney Int 66:668-675, 2004
23. SHIN G-T, KIM WH, YIM H, et al: Effects of suppressing intrarenal angiotensinogen on renal transforming growth factor B1 expression in acute ureteral obstruction. Kidney Int 67:897-980, 2005
24. WOLF G, RITZ E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int 67:799-812, 2005
25. ADAMCZAK M, GROSS ML, KRTIL J, et al: Reversal of glomerulosclerosis after high dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 14:2833-2842, 2003
26. WATTS K, SPITERI M: Connective tissue growth factor expression and induction by transforming growth factor-β is abrogated by simvastatin via a Rho signaling mechanism. Am J Physiol Lung Cell Mol Physiol 287:L1323-L3332, 2004
27. ZOJA C, BENIGNI A, CAMOZZI D, et al: Combining lisinopril and L-arginine slows disease progression and reduces endothelin-1 in passive Heyman nephritis. Kidney Int 64:857-863, 2003
28. REYES AA, PURKERSON ML, KARL I, KLAHR S: Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis 20:168-176, 1992
29. ASHAB I, PEER G, BLUM M, et al: Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int 47:1515-1521, 1995
30. RODRÍGUEZ-ITURBE B, VAZIRI ND, HERRERA-ACOSTA J, JOHNSON RJ: Oxidative stress, renal infiltration of immune cells and salt-sensitive hypertension: All for one and one for all. Am J Physiol Renal Physiol 286:F606-F616, 2004
31. RANGAN GK, WANG Y, HARRIS DC: Pharmacologic modulators of nitric oxide exacerbate tubulointerstitial inflammation in proteinuric rats. J Am Soc Nephrol 12:1696-1705, 2001
32. FUJIHARA CK, MALHEIROS DM, ZATZ R, NORONHA ID: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 54:1510-1519, 1998
33. ROMERO F, RODRIGUEZ-ITURBE B, PARRA G, et al: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 55:945-955, 1999
34. FUJIHARA CK, DE LOURDES NORONHA I, MALHEIROS, et al: Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 11:283-290, 2000
35. RODRIGUEZ-ITURBE B, QUIROZ Y, SHAHKARAMI A, et al: Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat. Kidney Int 68:1041-1047, 2005
36. XU Z-G, LANTING L, VAZIRI ND, et al: Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney. Circulation 111:1962-1969, 2005
37. VANEGAS V, FERREBUZ A, QUIROZ Y, RODRIGUEZ-ITURBE B: Hypertension in Page (cellophane-wrapped) kidney is due to interstitial nephritis. Kidney Int 68:1161-1170, 2005
38. HAUSER IA, RENDERS L, RADEKE H-H, et al: Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 14:58-63, 1999
39. BADID C, VINCENT M, MCGREGOR B, et al: Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 58:51-61, 2000
40. TAO Y, KIM J, SCHRIER RW, EDELSTEIN CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16:46-51, 2005
41. NEGRI AL: Prevention of progressive fibrosis in chronic renal diseases: Antifibrotic agents. J Nephrol 17:496-503, 2004
42. MCDONALD GA, SARKAR P, RENNKE H, et al: Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo. Am J Physiol Renal Physiol 285:F59-F67, 2003
43. GARBER SL, MIROCHNIK Y, BRECKLIN CS, et al: Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int 59:876-872, 2001
44. SHIMIZU H, MARUYAMA S, YUZAWA Y, et al: Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 14:1496-1505, 2003
45. TAKASE O, HIRAHASHI J, TAKAYANAGI A, et al: Gene transfer of truncated IκBα prevents tubulointerstitial injury. Kidney Int 63:501-513, 2003
46. WOLF SC, BREHM BR, GASCHKER P, et al: Protective effects of endothelin antagonists in chronic renal failure. Nephrol Dial Transplant 14(Suppl 4):S29-30, 1999
47. ARIMA S, KOHAGURA K, XU HL, et al: Non-genomic vascular action of aldosterone in glomerular microcirculation. J Am Soc Nephrol 14:2255-2263, 2003
48. SCHAIER M, JOCKS T, GRÖNE HJ, et al: Retinoid agonist isotretinoin ameliorate obstructive renal injury. J Urol 170:1398-1402, 2003
49. KHULMANN A, HAAS CS, GROSS ML, et al: 1,25-dihydroxyvitamin D decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 286:F526-F533, 2004
50. KANG DH, HUGHES J, MAZZALI M, et al: Impaired angiogenesis in the remnant kidney model. II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12:1448-1457, 2001
51. KANG DH, PARK EY, YU ES, et al: Renoprotective effect of erythropoietin (EPO): Possibly via an amelioration of renal hypoxia with stimulation of angiogenesis in the kidney. Kidney Int 67:1683, 2005
52. LIU Y, RAJUR K, TOLBERT E, DWORKIN LD: Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int 58:2028-2043, 2000
53. MIZUNO S, MATSUMOTO K, WEN J, NAKAMURA T: Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 59:1304-1314, 2001
54. 1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9:964-968, 2003
55. WANG S, CHEN Q, SIMON TC, et al: Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 63:2037-2049, 2003
56. NAGATOYA K, MORIYAMA T, KAWADA N, et al: Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 61:1684-1695, 2002
57. ZIYADEH FN, HOFFMAN BB, HAN DC, et al: Long-term prevention of renal insufficiency, excess matrix expression and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020, 2000
58. YOKOI H, MUKOYAMA M, NAGAE T, et al: Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 15:1430-1440, 2004
59. WANG S, WILKES MC, LEOF EB, HIRSCHBERG R: Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J 19:1-11, 2005